Beyond fatigue: Assessing variables associated with sleep problems and use of sleep medications in multiple sclerosis

Alyssa M Bamer, Kurt L Johnson, Dagmar A Amtmann, George H Kraft, Alyssa M Bamer, Kurt L Johnson, Dagmar A Amtmann, George H Kraft

Abstract

BACKGROUND: Recent research indicates that sleep disturbances are common in persons with multiple sclerosis (MS), though research to date has primarily focused on the relationship between fatigue and sleep. In order to improve treatment of sleep disorders in MS, a better understanding of other factors that contribute to MS sleep disturbance and use of sleep medications in this population is needed. METHODS: Individuals with MS (N = 473) involved in an ongoing self-report survey study were asked to report on use of over-the-counter and prescription sleep medications. Participants completed the Medical Outcomes Study Sleep (MOSS) scale and other common self-report symptom measures. Multiple regression was used to evaluate factors associated with sleep problems and descriptive statistics were generated to examine use of sleep medications. RESULTS: The mean score on the MOSS scale was 35.9 (standard deviation, 20.2) and 46.8% of the sample had moderate or severe sleep problems. The majority of participants did not use over-the-counter (78%) or prescription (70%) sleep medications. In a regression model variables statistically significantly associated with sleep problems included depression, nighttime leg cramps, younger age, pain, female sex, fatigue, shorter duration of MS, and nocturia. The model explained 45% of the variance in sleep problems. Of the variance explained, depression accounted for the majority of variance in sleep problems (33%), with other variables explaining significantly less variance. CONCLUSIONS: Regression results indicate that fatigue may play a minor role in sleep disturbance in MS and that clinicians should consider the interrelationship between depression and sleep problems when treating either symptom in this population. More research is needed to explore the possibility of under-treatment of sleep disorders in MS and examine the potential effectiveness of nonpharmaceutical treatment options.

References

    1. National Multiple Sclerosis Society Who gets MS? 2010. Available from: . Accessed March 9, 2010.
    1. Crayton HJ, Rossman HS. Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther. 2006;28(4):445–460.
    1. Bamer AM, Johnson KL, Amtmann D, Kraft GH. Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler. 2008;14(8):1127–1130.
    1. Tachibana N, Howard RS, Hirsch NP, Miller DH, Moseley IF, Fish D. Sleep problems in multiple sclerosis. Eur Neurol. 1994;34(6):320–323.
    1. Manocchia M, Keller S, Ware JE. Sleep problems, health-related quality of life, work functioning and health care utilization among the chronically ill. Qual Life Res. 2001;10(4):331–345.
    1. Merlino G, Fratticci L, Lenchig C, et al. Prevalence of ‘poor sleep’ among patients with multiple sclerosis: an independent predictor of mental and physical status. Sleep Med. 2009;10(1):26–34.
    1. Attarian HP, Brown KM, Duntley SP, Carter JD, Cross AH. The relationship of sleep disturbances and fatigue in multiple sclerosis. Arch Neurol. 2004;61(4):525–528.
    1. Hossain JL, Ahmad P, Reinish LW, Kayumov L, Hossain NK, Shapiro CM. Subjective fatigue and subjective sleepiness: two independent consequences of sleep disorders? J Sleep Res. 2005;14(3):245–253.
    1. Kaynak H, Altintas A, Kaynak D, et al. Fatigue and sleep disturbance in multiple sclerosis. Eur J Neurol. 2006;13(12):1333–1339.
    1. Merkelbach S, Schulz H. What have fatigue and sleepiness in common? J Sleep Res. 2006;15(1):105–106.
    1. Stanton BR, Barnes F, Silber E. Sleep and fatigue in multiple sclerosis. Mult Scler. 2006;12(4):481–486.
    1. Strober LB, Arnett PA. An examination of four models predicting fatigue in multiple sclerosis. Arch Clin Neuropsychol. 2005;20(5):631–646.
    1. Benca RM, Peterson MJ. Insomnia and depression. Sleep Med. 2008;9(Suppl 1):S3–S9.
    1. Pallesen S, Nordhus IH, Omvik S, Sivertsen B, Tell GS, Bjorvatn B. Prevalence and risk factors of subjective sleepiness in the general adult population. Sleep. 2007;30(5):619–624.
    1. Fleming WE, Pollak CP. Sleep disorders in multiple sclerosis. Semin Neurol. 2005;25(1):64–68.
    1. Johnson KL, Bamer AM, Fraser RF. Disease and demographic characteristics associated with unemployment among working age adults with multiple sclerosis. International Journal of MS Care. 2009;11(3):137–143.
    1. Johnson KL, Bamer AM, Yorkston KM, Amtmann D. Use of cognitive aids and other assistive technology by individuals with multiple sclerosis. Disabil Rehabil Assist Technol. 2009;4(1):1–8.
    1. Hays R, Stewart A. Sleep measures. In: Stewart A, Ware J, editors. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992.
    1. Spritzer KL, Hays RD. MOS Sleep Scale: A Manual for Use and Scoring. Los Angeles, CA: RAND; 2003. Version 1.0.
    1. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA. 1999;282(18):1737–1744.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–613.
    1. Cannon DS, Tiffany ST, Coon H, Scholand MB, McMahon WM, Leppert MF. The PHQ-9 as a brief assessment of lifetime major depression. Psychol Assess. 2007;19(2):247–251.
    1. Lamers F, Jonkers CC, Bosma H, Penninx BW, Knottnerus JA, van Eijk JT. Summed score of the Patient Health Questionnaire-9 was a reliable and valid method for depression screening in chronically ill elderly patients. J Clin Epidemiol. 2008;61(7):679–687.
    1. Martin A, Rief W, Klaiberg A, Braehler E. Validity of the Brief Patient Health Questionnaire Mood Scale (PHQ-9) in the general population. Gen Hosp Psychiatry. 2006;28(1):71–77.
    1. Fann JR, Bombardier CH, Dikmen S, et al. Validity of the Patient Health Questionnaire-9 in assessing depression following traumatic brain injury. J Head Trauma Rehabil. 2005;20(6):501–511.
    1. Lowe B, Spitzer RL, Grafe K, et al. Comparative validity of three screening questionnaires for DSM-IV depressive disorders and physicians’ diagnoses. J Affect Disord. 2004;78(2):131–140.
    1. Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis. Can J Neurol Sci. 1994;21(1):9–14.
    1. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis. 1994;18(Suppl 1):S79–S83.
    1. Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X. Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult Scler. 2005;11(2):198–202.
    1. Bowen J, Gibbons L, Gianas A, Kraft GH. Self-administered expanded disability status Scale with functional system scores correlates well with a physician-administered test. Mult Scler. 2001;7(3):201–206.
    1. Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. Pain. 1992;50(2):133–149.
    1. Jensen M, Karoly P. Self-report scales and procedures for assessing pain in adults. In: Turk DC, Melzack R, editors. Handbook of Pain Assessment. 2nd ed. New York, NY: Guilford; 2000. pp. 135–151.
    1. Ferri R, Lanuzza B, Cosentino FI, et al. A single question for the rapid screening of restless legs syndrome in the neurological clinical practice. Eur J Neurol. 2007;14(9):1016–1021.
    1. Johnson EO, Roehrs T, Roth T, Breslau N. Epidemiology of alcohol and medication as aids to sleep in early adulthood. Sleep. 1998;21(2):178–186.
    1. Roehrs T, Hollebeek E, Drake C, Roth T. Substance use for insomnia in metropolitan Detroit. J Psychosom Res. 2002;53(1):571–576.
    1. Allen KD, Renner JB, DeVellis B, Helmick CG, Jordan JM. Racial differences in sleep medication use: a cross-sectional study of the Johnston County Osteoarthritis Project. Ann Pharmacother. 2008;42(9):1239–1246.
    1. Tononi G, Cirelli C. Sleep function and synaptic homeostasis. Sleep Med Rev. 2006;10(1):49–62.
    1. Burke M, Mahurin R, Bowen JD. Differential brain compensation for cognitive versus motor processes in early relapsing-remitting multiple sclerosis subjects without clinical impairment. Mult Scler. 2006;12:S43–S44.
    1. Doerr JP, Hirscher V, Riemann D, Voderholzer U. [Disturbances of slow-wave sleep and psychiatric disorders.] Nervenarzt. 2010;81(3):347–354.
    1. Stepanski EJ, Wyatt JK. Use of sleep hygiene in the treatment of insomnia. Sleep Med Rev. 2003;7(3):215–225.
    1. Dolan DC, Taylor DJ, Bramoweth AD, Rosenthal LD. Cognitive-behavioral therapy of insomnia: A clinical case series study of patients with co-morbid disorders and using hypnotic medications. Behav Res Ther. 2010;48(4):321–327.
    1. Becker PM, Sattar M. Treatment of sleep dysfunction and psychiatric disorders. Curr Treat Options Neurol. 2009;11(5):349–357.
    1. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of insomnia. CMAJ. 2000;162(2):225–233.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir